anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
New defense elicitor peptides have been identified which control Xylella fastidiosa infections in almond. Xylella fastidiosa is a plant pathogenic bacterium that has been introduced in the European Union (EU), threatening the agricultural economy of relevant Mediterranean crops such as almond (Prunus dulcis). Plant defense elicitor peptides would be promising to manage diseases such as almond leaf scorch, but their effect on the host has not been fully studied. In this work, the response of almond plants to the defense elicitor peptide flg22-NH2 was studied in depth using RNA-seq, confirming the activation of the salicylic acid and abscisic acid pathways. Marker genes related to the response triggered by flg22-NH2 were used to study the effect of the application strategy of the peptide on almond plants and to depict its time course. The application of flg22-NH2 by endotherapy triggered the highest number of upregulated genes, especially at 6 h after the treatment. A library of peptides that includes BP100-flg15, HpaG23, FV7, RIJK2, PIP-1, Pep13, BP16-Pep13, flg15-BP100 and BP16 triggered a stronger defense response in almond plants than flg22-NH2. The best candidate, FV7, when applied by endotherapy on almond plants inoculated with X. fastidiosa, significantly reduced levels of the pathogen and decreased disease symptoms. Therefore, these novel plant defense elicitors are suitable candidates to manage diseases caused by X. fastidiosa, in particular almond leaf scorch.
We report a case of a severe ear infection in a 35-year-old man treated with ixekizumab for psoriasis. Ixekizumab is a humanized monoclonal antibody that selectively prevents the interaction between interleukin 17 A and its receptor. Biologicals like ixekizumab are used to achieve symptom relief in autoimmune diseases including psoriasis. Unlike the mild upper respiratory tract infections usually described as side-effects of this treatment, we report a case of a patient who presented with a severe otitis media, complicated with a facial paresis and nasopharyngeal abscess. To the best of our knowledge, this is the first case presenting a severe, complicated ear infection as a possible side effect of ixekizumab. We conclude that when using ixekizumab, vigilance for upper airway infections is needed and if necessary, interruption of therapy should be considered. However, further research is needed to confirm this hypothesis.
BACKGROUND: Green nanoparticles are considered to be an effective strategy for improving phytochemicals and raising productivity in soil infected by root-knot nematodes. This work aims to understand the characteristics of certain nanomaterials, including non-iron (nFe), green non-iron (GnFe), and green magnetic nanobiochar (GMnB), and the effect of adding them at 3 and 6 mg kg- 1 on phytochemicals and tomato (Solanum lycopersicum) plant growth in soils infected by root-knot nematodes.
RESULTS: Spectroscopic characterization of nanomaterials showed that nFe, GnFe, and GMnB contained functional groups (e.g., Fe-O, S-H, C-H, OH, and C = C) and possessed a large surface area. Application of GMB at 6 mg kg- 1 was the most efficient treatment for increasing the phytochemicals of the tomato plant, with a rise of 123.2% in total phenolic, 194.7% in total flavonoids, 89.7% in total carbohydrate, 185.2% in total free amino acids, and 165.1% in total tannin compared to the untreated soil. Tomato plant growth and attributes increased with increasing levels of soil nano-amendment in this investigation. The addition of GnFe3 and GnFe6 increased the reduction of root galls of root-knot nematodes by 22.44% and 17.76% compared with nFe3 and nFe6, respectively. The inclusion of the examined soil nano-amendments increased phytochemicals and reduced the total number of root-knot nematodes on tomato plants at varying rates, which played a significant role in enhancing tomato growth.
CONCLUSIONS: In conclusion, treating tomato plants with GnFe or GMnB can be used as a promising green nanomaterial to eliminate root-knot nematodes and increase tomato yield in sandy clay loam soil.
INTRODUCTION: A Programme Science approach that prioritizes populations who will benefit most and ensuring resources are allocated to programmes that meet the needs of those populations will bring an equity focus to research. Gay men and other men who have sex with men, people who use drugs, sex workers of all genders, and trans and gender-diverse people, defined by the Joint United Nations Programme on HIV/AIDS (UNAIDS) and The Global Fund to Fight AIDS, Tuberculosis and Malaria (Global Fund) as key populations, have been disproportionately impacted since the start of the HIV pandemic. Through documenting community experiences from global key population-led networks, the authors explore the potential value and impact of community-led organizations and service delivery as critical components in effective HIV and Sexually Transmitted infections (STI) programmes.
DISCUSSION: Through advocacy and research interventions, global key population networks have identified barriers against scaling up interventions for criminalized and marginalized communities, as well as highlighted solutions. The authors examine some of the current barriers to meaningful involvement of communities and the scaling up of community-led programmes that need to be addressed if Programme Science is to maintain an equity lens and the needs of key populations are to be met and highlight the need to make visible community engagement and participation in embedded research and Programme Science.
CONCLUSIONS: The Programme Science approach provides an important opportunity to understand practical issues that will increase effective coverage in the implementation of public health and other interventions, which will require the prioritizing of key populations and their priorities in HIV and STI programmes. It will require extensive time and work to build relationships, increase capacity and share power. Where this has already happened, it has resulted in positive outcomes, including better health outcomes, reduced stigma, increased agency for key populations, and built community-led organizations and responses.
A bladder system and apparatus for use with a beverage barrel or container, to reduce undesirable head-space in a wooden container of a beverage, especially a fermented beverage, such as wine. The system continuously protects the beverage contained in a wooden barrel from the harmful effects of oxidation at the air-to-fluid interface in the head-space and compensates for ullage, attributable to evaporation, leakage or sampling losses. The system includes an inflation stem connected to a barrel bladder inflatable by filling with an inflation gas. The inflation stem includes a liquid level sensor and inserts into a bung opening. The fluid level is sensed and a gas valve opens to fill the bladder, reducing head-space within the barrel. The system can combine the control of several barrels and optionally with other sensors, to create a barrel monitoring and control network.
The invention provides a vaccine including an isolated AIs protein family member having cell adhesion activity, or an immunogenic fragment thereof, with an adjuvant in a pharmaceutically acceptable medium. The invention also provides a method of treating or preventing hematogenously disseminated or mucocutaneous candidiasis. The method includes administering an immunogenic amount of a vaccine an isolated AIs protein family member having cell adhesion activity, or an immunogenic fragment thereof, in a pharmaceutically acceptable medium. A method of treating or preventing disseminated candidiasis also is provided that includes administering an effective amount of an isolated AIs protein family member having cell adhesion activity, or an functional fragment thereof, to inhibit the binding or invasion of Candida to a host cell or tissue. The AIs protein family member can be derived from a Candida strain selected from the group consisting of Candida albicans, Candida krusei, Candida tropicalis, Candida glabrata and Candida parapsilosis and the AIs protein family member includes AIs Ip, Als3p, Als5p, AlsÌp, Als7p or Als9p. Also provided is a method of treating or preventing Staphylococcus aureus infections. The method includes administering an immunogenic amount of a vaccine an isolated AIs protein family member having cell adhesion activity, or an immunogenic fragment thereof, in a pharmaceutically acceptable medium.
Transmembrane protein 268 (TMEM268) is a novel, tumor growth-related protein first reported by our laboratory. It interacts with the integrin subunit β4 (ITGB4) and plays a positive role in the regulation of the ITGB4/PLEC signaling pathway. Here, we investigated the effects and mechanism of TMEM268 in anti-infectious immune response in mice. Tmem268 knockout in mice aggravated cecal ligation and puncture-induced sepsis, as evidenced by higher bacterial burden in various tissues and organs, congestion, and apoptosis. Moreover, Tmem268 deficiency in mice inhibited phagocyte adhesion and migration, thus decreasing phagocyte infiltration at the site of infection and complement-dependent phagocytosis. Further findings indicated that TMEM268 interacts with CD11b and inhibits its degradation via the endosome-lysosome pathway. Our results reveal a positive regulatory role of TMEM268 in β2 integrin-associated anti-infectious immune responses and signify the potential value of targeting the TMEM268-CD11b signaling axis for the maintenance of immune homeostasis and immunotherapy for sepsis and related immune disorders.
The best fixation method for open tibial fractures remains controversial. The current standard treatment options recommended the use of intramedullary nail for treating such fractures. Recent studies also showed favorable results for the use of plates in managing open tibial fractures. However, it is unknown whether locking plate or intramedullary nail fixation will result in lower complication rates and better function.

This study is a prospective, randomized trial to compare the safety and efficiency of minimally invasive plate osteosynthesis and reamed intramedullary nails in treating type I-II open tibial shaft fractures. The investigators hypothesize that neither intervention resulted in a superior disability rating at 12 months. Outcomes evaluated will include the rate of infection, the number of re-hospitalization for the complication, the time to bone healing, Patient-Reported outcome and quality of life and other complications.
The primary aim of this study is to compare the effect of an individualized adherence intervention (TI) and a structured adherence intervention (TS) to usual care on adherence to antiretroviral therapy in persons infected with HIV (PWHIV). The secondary aims address the relationship between adherence and quality of life (QOL), and between adherence and clinical response. The exploratory aims focus on examining the effect of self-efficacy on the relationship between the intervention and adherence, the effect of adherence on the relationship between self-efficacy and outcomes (clinical response and quality of life), as well as the effects of symptoms, alcohol and/or drug use, chronic interpersonal problems, mood, social support, optimism, perceived burden of medication regimen, perceived stigma, purpose in life, co-morbidity, personality, literacy, and intimate partner abuse on self-efficacy, and psychometric analyses of the instruments. The sample of 300 (plus 51 dropouts) PWHIV who are taking antiretroviral therapy and without cognitive dysfunction will be randomly assigned to one of two treatment arms. Those individuals who are deemed to be 100% adherers (approximately 25-50) will be assigned to the control group, but will be followed separately as a natural history substudy and interviewed. Data will be collected at baseline, post-treatment, post-maintenance, post-booster, and 18 months. Electronic event monitors, diaries, the Self-reported Medication-taking Scale, and the ACTG Adherence Follow-up Questionnaire will be used to assess adherence. The Digit Vigilance Test will be used to assess the effect of sustained attention on adherence. QOL will be measured using the MOS-HIV, the Satisfaction with Life Scale, and the Perception of Illness Visual Analogue Scale. Clinical response will be assessed using viral load, CD4 T-cell count, AIDS defining conditions, and hospitalizations. Variables influencing self-efficacy (measured with an investigator-developed Self-efficacy Scale) will be examined: symptoms ( CRCD Symptom Checklist), alcohol and/or drug use (AUDIT), chronic interpersonal problems (IIP), social support (Interpersonal Support Evaluation List), optimism (Life Orientation Test), anxiety (Beck Anxiety Inventory) and Beck Depression Inventory II), perceived burden of regimen (visual analog scales), perceived stigma (Perceived Stigma of HIV Scale), purpose in life (Purpose in Life Scale), co-morbidity (CRCD Co-Morbidity Scale), personality characteristics (NEO-FFI), health literacy (Test of Functional Health Literacy in Adults), knowledge about HIV medication adherence (HIV Medication Adherence Knowledge), and intimate partner abuse (Abuse Assessment Screen). A repeated measures model with planned comparisons will be used to test the hypotheses for the primary aim. Structural equation modeling will be used to examine the relationships identified in the secondary and exploratory aims. PWHIV who adhere to their therapy may live longer, require fewer hospitalizations, and have an improved QOL.
A therapeutically active dihaloaminobenzylamine of formula (I) (where Y is H) and its acid addn. salt, more partic. hydrochloride is prepd. by reacting 2,4-dibromo-6- (N-cyclohexyl-N-methyl) aminomethyl benzoic acid of formula (I) (where Y is COOH). with hydrazoic acid (HN3) in an inert organic solvent, e.g. chloroform, which contains conc. sulphuric acid, polyphosphoric acid or another strong acid, at a temp. of 35-100 degrees C with the hydrazoic acid reacting in the nascent state by adding to the named soln. a salt of hydrazoic acid, e.g. sodium azide, whereupon, if desired, the formed 2-amino-3,5-dibromo-N-cyclohexyl-N-methylbenzylamine is by a usual method, converted into an acid addn. salt.
This quasi-experimental study was conducted in the Obstetrics and Gynecology Department of Services Institute of Medical Sciences (SIMS), Lahore, Pakistan, to compare the impact of Kangaroo Mother Care (KMC) versus Conventional Care (CC) on low birth weight infants. A total of 400 infants (200 in each group) born between January 2020 and December 2022 were included in the study, with participants selected based on specific inclusion criteria and informed consent obtained. KMC involved continuous skin-to-skin contact between mother and infant during the hospital stay and continued at home for at least 8 hours daily. The follow-up schedule included appointments at six weeks after birth, monthly visits until six months of age, and quarterly visits until the infants reached one year of age. During these visits, the study collected data on infant growth, developmental milestones, breastfeeding practices, and vaccination status. The study was ethically approved by the research ethics committee, and data collection was conducted during scheduled follow-up visits to the outpatient department.
BACKGROUND: The original ROCSS trial demonstrated a significant reduction in clinically detectable incisional hernias at 2 years in patients receiving prophylactic biological mesh during stoma closure. ROCSS-Ex was designed to investigate the 5-8-year cost-effectiveness of mesh in the surviving cohort using an abdominal wall-specific quality of life score.
METHODS: Eligible participants from original UK centres were identified. The primary outcome (abdominal wall-specific quality of life) was measured using the HerQLes score and EQ-5D-5L. Assessors remained blind to patients' original allocation, even if the patient was aware of their treatment.
RESULTS: Of the original 790 patients, 598 were available for long-term follow-up. HerQLes scores were available for 396 patients (no mesh: 191, mesh: 205). There was no difference in primary outcome between the two groups (mean difference of 1.48, 95% c.i. (-2.35, 5.32), P = 0.45) and no cost benefit of routine insertion of prophylactic biological mesh across the entire cohort in the long term. However, patients who received mesh experienced significantly fewer stoma site complications within the first 3 years after reversal and needed fewer surgical reinterventions (32 versus 54 for the no mesh group; incidence rate ratio of 0.55, 95% c.i. (0.31, 0.97), P = 0.04).
CONCLUSIONS: ROCSS-Ex has shown equivocal outcomes for prophylactic mesh insertion versus standard repair on abdominal wall-specific quality of life 5-8 years after surgery. As most reinterventions occurred within the first 3 years post-surgery, there may be a role for prophylactic mesh in a subset of patients who would be most adversely affected by repeated surgery early on.
TRIAL REGISTRATION: ISRCTN25584182 (http://www.clinicaltrials.gov).
Extn. of antigenic complexes comprises solubilising the walls of microorganisms (previously purified) by the simultaneous action of sodium desocycholate (0.5-5 mg per mg of proteins), lysozyme (1 mg/ml) and sodium ethylene-diaminotetracetate (25 mmoles). Pref. the solubilisation is effected at neutral pH and 20 degrees C for 12-24 hrs.; the extract is then centrifuged and the soluble supernatant fraction is used directly as antigen source without removal of the solubilising agent. Prod. obtd. comprises a pseudomicellar reassociation (formed by hydrophobic interaction) of hydrophobic proteins, lepopolysaccharides and peptidoglycons in the presence of sodium desoxycholate to give inter- and intra-specific antigenic complexes in which the antigenic sites are not denaturised. The sodium desoxycholate remaining in the prod. aids formation of the soluble, hydrophobic antigenic complexes and helps protect them against protease contaminants. Used for prepn. of vaccines e.g. upper respiratory and bronchial tract vaccines. The process allows large scale prepn. of antigen complexes using large scale homogenisers, centrifuges etc. The prod. is a new hybrid complex prepd. from known strains which preserves the structural integrity qf the antigen molecule and allows more rapid recognition by the specialised cells of the organism.
The placebo tablets will be identical to the IMU-838 tablets in terms of appearance, constitution of inactive ingredients, and packaging. Patients who have received placebo during the induction phase will be 're-randomized' to continue to receive placebo (in a blinded fashion).
This is an observational prospective cohort study of adults with autosomal dominant polycystic kidney disease (ADPKD) with estimated GFR at least 15cc/min/1.73m2. There are no therapeutic interventions in this observational cohort study.
The present invention discloses a twin lamb agnet for increasing the propagation efficiency of sheep and goats in the production of animal husbandry. A testosterone-3-carboxymethyl oxime-bovine serum protein emulsifying agent is matched with powder obtained by grinding Chinese medicinal herbs of the weight proportion of 30% of epimedium herb, 20% of motherwort, 20% of angelica, 20% of tremolite or tremolite asbestos and 10% of milkvetch root and mineral substances. After the testosterone-3-carboxymethyl oxime-bovine serum protein emulsifying agent is injected to the sheep, ewes generate corresponding immune bodies which can neutralize testosterone hormones in blood in vivo to make egg follicles on ovaries continuously developed; ewes' physiological statuses can be changed by feeding the Chinese medicinal herbs. The ewes can heat, ovulate, conceive and lamb in an anestrous season. The present invention makes the ewes produce one more ovum and produce one more lamb than a normal state; single-birth ewes produce twin lambs and twin-birth ewes produce three lambs; in a breeding season, the present invention relates to 10% higher than the inventions of fedundin and a lamb increasing agent. The present invention achieves the effect of 30 to 40% higher than normal propagation ewes.
Improving the powdery mildew resistance of bitter gourd is highly important for achieving high yield and high quality. To better understand the genetic basis of powdery mildew resistance in bitter gourd, this study analyzed 300 lines of recombinant inbred lines (RILs) formed by hybridizing the powdery mildew-resistant material MC18 and the powdery mildew-susceptible material MC402. A high-density genetic map of 1222.04 cM was constructed via incorporating 1,996,505 SNPs generated by resequencing data from 180 lines, and quantitative trait locus (QTL) positioning was performed using phenotypic data at different inoculation stages. A total of seven QTLs related to powdery mildew resistance were identified on four chromosomes, among which qPm-3-1 was detected multiple times and at multiple stages after inoculation. By selecting 18 KASP markers that were evenly distributed throughout the region, 250 lines and parents were genotyped, and the interval was narrowed to 207.22 kb, which explained 13.91% of the phenotypic variation. Through RNA-seq analysis of the parents, 11,868 differentially expressed genes (DEGs) were screened. By combining genetic analysis, gene coexpression, and sequence comparison analysis of extreme materials, two candidate genes controlling powdery mildew resistance in bitter gourd were identified (evm.TU.chr3.2934 (C3H) and evm.TU.chr3.2946 (F-box-LRR)). These results represent a step forward in understanding the genetic regulatory network of powdery mildew resistance in bitter gourd and lay a molecular foundation for the genetic improvement in powdery mildew resistance.
Cysteamine bitartrate delayed-release capsules were administered twice daily following a dose-escalation design with a progressive weekly dose increase over the first 6 weeks. The starting dose was 0.2 g/m²/day, up to a maximum dose of 1.3 g/m²/day. Participants remained on their highest tolerated dose until Week 24.
Laser sources have established their potential effect in inducing hair regrowth. No large cohort study has evaluated the effect of ablative fractional 2940-nm erbium yttrium aluminum garnet (Er: YAG) laser in the treatment of androgenetic alopecia (AGA). To investigate the efficacy and safety of the ablative fractional 2940-nm Er: YAG laser in combination with medication therapy for the treatment of AGA. We performed a retrospective study between first July 2021 to 30th December 2021. All included patients received oral finasteride and topical minoxidil, or combined with six sessions of Er: YAG laser at 2-week intervals. Patients were divided into medication or combined therapy groups. The efficacy of the two therapies was evaluated by the investigator's Global Assessment (IGA) scores and the patient's Likert satisfaction scale at week 12 and week 24. Changes in total, terminal and villous hair count, total and terminal hair diameter, and AGA grade were also recorded. Adverse events were evaluated at each follow-up. A total of 192 male patients with AGA were included, including 67 receiving combination treatment, and 125 receiving medication treatment. At week 24, the combination treatment afforded superior outcomes in the IGA score, patient's global assessment, total and terminal hair counts, and diameters (all P<0.05). No severe adverse events were reported in both groups. The combined therapy of ablative fractional Er: YAG laser and medication was superior in treating male AGA than single medication therapy without serious adverse effects.